9-hydroxy-10,12-octadecadienoic acid has been researched along with Cardiometabolic Syndrome in 1 studies
*Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berthelot, P; Chavatte, P; Desreumaux, P; Farce, A; Furman, C; Lebègue, N; Millet, R; Pirat, C; Renault, N; Speca, S; Yous, S | 1 |
1 review(s) available for 9-hydroxy-10,12-octadecadienoic acid and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.
Topics: Animals; Humans; Ligands; Metabolic Syndrome; Models, Molecular; Molecular Targeted Therapy; Peroxisome Proliferator-Activated Receptors | 2012 |